Source:http://linkedlifedata.com/resource/pubmed/id/15004434
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-4-15
|
pubmed:abstractText |
Omapatrilat inhibits neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE). We compared the effects of omapatrilat (40 mg/kg/day, p.o.) to fosinopril (40 mg/kg/day, p.o.) on flow-induced vascular remodeling in New Zealand genetically hypertensive (GH) rats. Both drugs equally reduced blood pressure (BP) initially, but systolic BP and pulse pressure were reduced more by omapatrilat after 1 week. Carotid remodeling was induced by partial ligation of the left common carotid artery (LCA). There was little remodeling in untreated GH rats - measured as outer diameter to body weight (OD/BW vs. before ligation): 97 +/- 1% of initial LCA (low flow) and 107 +/- 3% of initial right common carotid artery (RCA, high flow). In contrast, OD/BW increased to 118 +/- 5% (p < 0.05) of initial RCA after omapatrilat versus 108 +/- 2% (p = 0.96) after fosinopril. The major change was increased RCA lumen area which was significantly larger in omapatrilat-treated animals (127% vs. control) than fosinopril-treated animals (103% vs. control). The increase in outward remodeling after omapatrilat treatment correlated weakly with vascular cGMP levels and decreased systolic BP. The results suggest that dual inhibition of NEP/ACE may have greater effects than ACE inhibition alone on vessel remodeling in hypertension.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Fosinopril,
http://linkedlifedata.com/resource/pubmed/chemical/Neprilysin,
http://linkedlifedata.com/resource/pubmed/chemical/Peptidyl-Dipeptidase A,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazepines,
http://linkedlifedata.com/resource/pubmed/chemical/omapatrilat
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1018-1172
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2004 S. Karger AG, Basel
|
pubmed:issnType |
Print
|
pubmed:volume |
41
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
148-56
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:15004434-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:15004434-Animals,
pubmed-meshheading:15004434-Blood Pressure,
pubmed-meshheading:15004434-Carotid Arteries,
pubmed-meshheading:15004434-Circadian Rhythm,
pubmed-meshheading:15004434-Drug Therapy, Combination,
pubmed-meshheading:15004434-Fosinopril,
pubmed-meshheading:15004434-Hypertension,
pubmed-meshheading:15004434-Male,
pubmed-meshheading:15004434-Neprilysin,
pubmed-meshheading:15004434-Peptidyl-Dipeptidase A,
pubmed-meshheading:15004434-Pyridines,
pubmed-meshheading:15004434-Rats,
pubmed-meshheading:15004434-Rats, Mutant Strains,
pubmed-meshheading:15004434-Regional Blood Flow,
pubmed-meshheading:15004434-Thiazepines,
pubmed-meshheading:15004434-Vascular Diseases
|
pubmed:articleTitle |
Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
|
pubmed:affiliation |
Center for Cardiovascular Research and Department of Medicine, University of Rochester, Rochester, NY 14642, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|